Highlights CEL-SCI Corporation

Equities

CVM

US1508376076

Market Closed - Nyse Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
1.21 ^USD	-.--%		-1.63%	-55.51%

15/05	CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
08/05	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	16/05	CI
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	08/05	CI
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05	CI
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	15/02	CI
CEL-SCI Corporation Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	06/02	CI
Cel-Sci Receives Pediatric Requirements Waiver for Multikine From European Medicines Agency	31/01	MT
North American Morning Briefing : S&P 500 Futures Just Shy of Record High	28/12	DJ
CEL-SCI Corporation Reports Earnings Results for the Full Year Ended September 30, 2023	22/12	CI
CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals	24/23/24	CI
CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain	23/23/23	CI
CEL-SCI Corporation Readies Its Multikine Manufacturing Facility for Commercial Scale Production	19/23/19	CI
Cel-Sci Files Request With UK Regulator for Approval Pathway of Multikine to Treat Head, Neck Cancer	05/23/05	MT
Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer	05/23/05	CI
Cel-Sci Submits Scientific Advice Filing to European Medicines Agency for Multikine in the Treatment of Head & Neck Cancer	26/23/26	CI
CEL-SCI Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	11/23/11	CI
CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikineâ€™s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer	12/23/12	CI
CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed	22/23/22	CI
CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine	15/23/15	CI
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	13/23/13	CI
CEL-SCI Corporation Reports New Data from Its Pivotal Phase 3 Study	08/23/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CEL-SCI Corporation

Equities

CVM

US1508376076

Highlights

Filters